Phospholipase D2-dependent inhibition of the nuclear hormone receptor PPARγ by cyclic phosphatidic acid

Molecular Cell

Volumn 39, Issue 3, 2010, Pages 421-432

  Tsukahara, Tamotsu ^a,f   Tsukahara, Ryoko ^a   Fujiwara, Yuko ^a   Yue, Junming ^a   Cheng, Yunhui ^a,g   Guo, Huazhang ^a   Bolen, Alyssa ^a   Zhang, Chunxiang ^a,g   Balazs, Louisa ^a   Re, Fabio ^a   Du, Guangwei ^b,h   Frohman, Michael A ^b   Baker, Daniel L ^c   Parrill, Abby L ^c,d   Uchiyama, Ayako ^e   Kobayashi, Tetsuyuki ^e   Murakami Murofushi, Kimiko ^e   Tigyi, Gabor ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b STONY BROOK UNIVERSITY   (United States)

^c University of Memphis   (United States)

^d UNIVERSITY OF MEMPHIS   (United States)

^e OCHANOMIZU UNIVERSITY   (Japan)

^f SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^h UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

DNA; Humdisease; Signaling

Indexed keywords

PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDIC ACID; PHOSPHOLIPASE D2;

ADIPOCYTE; ANIMAL CELL; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME ANALYSIS; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LIPOGENESIS; MACROPHAGE; MAMMAL CELL; MOUSE; NONHUMAN; PROTEIN FUNCTION; RAT;

3T3-L1 CELLS; ADIPOCYTES; ANIMALS; CELL DIFFERENTIATION; MACROPHAGES; MICE; NUCLEAR RECEPTOR CO-REPRESSOR 2; PHOSPHATIDIC ACIDS; PHOSPHOLIPASE D; PPAR GAMMA; RATS; TRANSCRIPTION, GENETIC;

MAMMALIA; RATTUS;

EID: 77955497628     PISSN: 10972765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molcel.2010.07.022     Document Type: Article

References (32)

1. Bligh E.G., Dyer W.J. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 1959, 37:911-917.
2. Boullier A., Gillotte K.L., Hörkkö S., Green S.R., Friedman P., Dennis E.A., Witztum J.L., Steinberg D., Quehenberger O. The binding of oxidized low density lipoprotein to mouse CD36 is mediated in part by oxidized phospholipids that are associated with both the lipid and protein moieties of the lipoprotein. J. Biol. Chem. 2000, 275:9163-9169.
3. Breen D.M., Chan K.K., Dhaliwall J.K., Ward M.R., Al Koudsi N., Lam L., De Souza M., Ghanim H., Dandona P., Stewart D.J., et al. Insulin increases reendothelialization and inhibits cell migration and neointimal growth after arterial injury. Arterioscler. Thromb. Vasc. Biol. 2009, 29:1060-1066.
4. Chakravarthy M.V., Lodhi I.J., Yin L., Malapaka R.R., Xu H.E., Turk J., Semenkovich C.F. Identification of a physiologically relevant endogenous ligand for PPARalpha in liver. Cell 2009, 138:476-488.
5. Cheng Y., Makarova N., Tsukahara R., Guo H., Shuyu E., Farrar P., Balazs L., Zhang C., Tigyi G. Lysophosphatidic acid-induced arterial wall remodeling: requirement of PPARgamma but not LPA1 or LPA2 GPCR. Cell Signal. 2009, 21:1874-1884.
6. Colley W.C., Sung T.C., Roll R., Jenco J., Hammond S.M., Altshuller Y., Bar-Sagi D., Morris A.J., Frohman M.A. Phospholipase D2, a distinct phospholipase D isoform with novel regulatory properties that provokes cytoskeletal reorganization. Curr. Biol. 1997, 7:191-201.
7. Du G., Huang P., Liang B.T., Frohman M.A. Phospholipase D2 localizes to the plasma membrane and regulates angiotensin II receptor endocytosis. Mol. Biol. Cell 2004, 15:1024-1030.
8. Eisen S.F., Brown H.A. Selective estrogen receptor (ER) modulators differentially regulate phospholipase D catalytic activity in ER-negative breast cancer cells. Mol. Pharmacol. 2002, 62:911-920.
9. Forman B.M., Tontonoz P., Chen J., Brun R.P., Spiegelman B.M., Evans R.M. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 1995, 83:803-812.
10. Friedman P., Haimovitz R., Markman O., Roberts M.F., Shinitzky M. Conversion of lysophospholipids to cyclic lysophosphatidic acid by phospholipase D. J. Biol. Chem. 1996, 271:953-957.
11. Hodgkinson C.P., Ye S. Microarray analysis of peroxisome proliferator-activated receptor-gamma induced changes in gene expression in macrophages. Biochem. Biophys. Res. Commun. 2003, 308:505-510.
12. Huang P., Frohman M.A. The potential for phospholipase D as a new therapeutic target. Expert Opin. Ther. Targets 2007, 11:707-716.
13. Kim J.H., Lee B.D., Kim Y., Lee S.D., Suh P.G., Ryu S.H. Cytosolic phospholipase A2-mediated regulation of phospholipase D2 in leukocyte cell lines. J. Immunol. 1999, 163:5462-5470.
14. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 1995, 270:12953-12956.
15. Li A.C., Brown K.K., Silvestre M.J., Willson T.M., Palinski W., Glass C.K. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J. Clin. Invest. 2000, 106:523-531.
16. Li Y., Zhang J., Schopfer F.J., Martynowski D., Garcia-Barrio M.T., Kovach A., Suino-Powell K., Baker P.R., Freeman B.A., Chen Y.E., Xu H.E. Molecular recognition of nitrated fatty acids by PPAR gamma. Nat. Struct. Mol. Biol. 2008, 15:865-867.
17. McIntyre T.M., Pontsler A.V., Silva A.R., St Hilaire A., Xu Y., Hinshaw J.C., Zimmerman G.A., Hama K., Aoki J., Arai H., Prestwich G.D. Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist. Proc. Natl. Acad. Sci. USA 2003, 100:131-136.
18. Moore K.J., Rosen E.D., Fitzgerald M.L., Randow F., Andersson L.P., Altshuler D., Milstone D.S., Mortensen R.M., Spiegelman B.M., Freeman M.W. The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nat. Med. 2001, 7:41-47.
19. Murakami-Murofushi K., Mukai M., Kobayashi S., Kobayashi T., Tigyi G., Murofushi H. A novel lipid mediator, cyclic phosphatidic acid (cPA), and its biological functions. Ann. N Y Acad. Sci. 2000, 905:319-321.
20. Nagy L., Tontonoz P., Alvarez J.G., Chen H., Evans R.M. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 1998, 93:229-240.
21. Nolte R.T., Wisely G.B., Westin S., Cobb J.E., Lambert M.H., Kurokawa R., Rosenfeld M.G., Willson T.M., Glass C.K., Milburn M.V. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 1998, 395:137-143.
22. Ricote M., Glass C.K. PPARs and molecular mechanisms of transrepression. Biochim. Biophys. Acta 2007, 1771:926-935.
23. Rother E., Brandl R., Baker D.L., Goyal P., Gebhard H., Tigyi G., Siess W. Subtype-selective antagonists of lysophosphatidic Acid receptors inhibit platelet activation triggered by the lipid core of atherosclerotic plaques. Circulation 2003, 108:741-747.
24. Sarraf P., Mueller E., Jones D., King F.J., DeAngelo D.J., Partridge J.B., Holden S.A., Chen L.B., Singer S., Fletcher C., Spiegelman B.M. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat. Med. 1998, 4:1046-1052.
25. Slaaby R., Du G., Altshuller Y.M., Frohman M.A., Seedorf K. Insulin-induced phospholipase D1 and phospholipase D2 activity in human embryonic kidney-293 cells mediated by the phospholipase C gamma and protein kinase C alpha signalling cascade. Biochem. J. 2000, 351:613-619.
26. Su W., Yeku O., Olepu S., Genna A., Park J.S., Ren H., Du G., Gelb M.H., Morris A.J., Frohman M.A. 5-Fluoro-2-indolyl des-chlorohalopemide (FIPI), a phospholipase D pharmacological inhibitor that alters cell spreading and inhibits chemotaxis. Mol. Pharmacol. 2009, 75:437-446.
27. Tontonoz P., Spiegelman B.M. Fat and beyond: the diverse biology of PPARgamma. Annu. Rev. Biochem. 2008, 77:289-312.
28. Tontonoz P., Nagy L., Alvarez J.G., Thomazy V.A., Evans R.M. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 1998, 93:241-252.
29. Tsukahara T., Tsukahara R., Yasuda S., Makarova N., Valentine W.J., Allison P., Yuan H., Baker D.L., Li Z., Bittman R., et al. Different residues mediate recognition of 1-O-oleyllysophosphatidic acid and rosiglitazone in the ligand binding domain of peroxisome proliferator-activated receptor gamma. J. Biol. Chem. 2006, 281:3398-3407.
30. Tzameli I., Fang H., Ollero M., Shi H., Hamm J.K., Kievit P., Hollenberg A.N., Flier J.S. Regulated production of a peroxisome proliferator-activated receptor-gamma ligand during an early phase of adipocyte differentiation in 3T3-L1 adipocytes. J. Biol. Chem. 2004, 279:36093-36102.
31. Yu C., Markan K., Temple K.A., Deplewski D., Brady M.J., Cohen R.N. The nuclear receptor corepressors NCoR and SMRT decrease peroxisome proliferator-activated receptor gamma transcriptional activity and repress 3T3-L1 adipogenesis. J. Biol. Chem. 2005, 280:13600-13605.
32. Zhang C., Baker D.L., Yasuda S., Makarova N., Balazs L., Johnson L.R., Marathe G.K., McIntyre T.M., Xu Y., Prestwich G.D., et al. Lysophosphatidic acid induces neointima formation through PPARgamma activation. J. Exp. Med. 2004, 199:763-774.